Skip to main content
. 2022 Jul 22;41(1):107–116. doi: 10.1200/JCO.22.00430

FIG 4.

FIG 4.

PFS according to KELIM (favorable or unfavorable) and treatment arms (VEL-throughout arm three v placebo [control] arms) in patients operated with PDS carrying tumors associated with (A) BRCA mutation or (B) BRCA wild-type HRD. HRD, homologous recombination deficiency; KELIM, elimination rate constant K; NA, not available; PDS, primary debulking surgery; PFS, progression-free survival; VEL, veliparib.